Crinetics Pharmaceuticals reports prelim Q4 revenue

Crinetics Pharmaceuticals

05/01/2026 13:09

Corrects throughout to say prelim Q4 net product revenue, not prelim Q4 net revenue

Overview

Pharmaceutical company's preliminary Q4 net product revenue exceeded $5 mln

Company reports positive Phase 2 CAH study results with atumelnant

Preliminary results subject to completion of financial closing procedures

Outlook

Company did not provide specific financial guidance for future quarters

Result Drivers

PALSONIFY LAUNCH - Strong U.S. launch execution led to over $5 mln in preliminary Q4 net product revenue, with >200 enrollment forms and broad prescriber base

ATUMELNANT RESULTS - Phase 2 CAH study showed 67% reduction in androstenedione levels and 88% of participants reduced glucocorticoid doses

FAVORABLE SAFETY PROFILE - Atumelnant was well-tolerated with no serious adverse events in Phase 2 CAH study

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 prelim net product revenue
$5 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc is $83.00, about 77.6% above its January 2 closing price of $46.73

Press Release: ID:nGNXbLX7BD

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)